[1]BESTARD MATAMOROS O, POVEDA MONJE R, IBERNON VILARM, et al.Systemic AA amyloidosis induced by benign neoplasms[J].Nefrologia, 2008, 28 (1) :93-98.
|
[2]PERFETTO F, MOGGI-PIGNONE A, LIVI R, et al.Systemic amyloidosis:a challenge for the rheumatologist[J].Nat Rev Rheumatol, 2010, 6 (7) :417-429.
|
[3]HU YL, PAN Y, XIN GJ, et al.Clinical diagnosis of patientswith hepatic amyloid degeneration[J].J Clin Hepatol, 2010, 26 (1) :65-66. (in Chinese) 胡玉琳, 潘煜, 辛桂杰, 等.4例肝淀粉样变性的临床特点和分析[J].临床肝胆病杂志, 2010, 26 (1) :65-66.
|
[4]COHEN AD, COMENZO RL.Systemic light-chain amyloidosis:advances in diagnosis, prognosis, and therapy[J].Hematology Am Soc Hematol Educ Program, 2010, 2010 (1) :287-294.
|
[5]SJOLANDER D, ROCKEN C, WESTERMARK P, et al.Establishing the fluorescent amyloid ligand h-FTAA for studying human tissues with systemic and localized amyloid[J].Amyloid, 2016, 23 (2) :98-108.
|
[6]HUANG X, WANG Q, JIANG S, et al.The clinical featuresand outcomes of systemic AL amyloidosis:a cohort of 231 Chinese patients[J].Clin Kidney J, 2015, 8 (1) :120-126.
|
[7]DISPENZIERI A, BUADI F, KUMAR SK, et al.Treatment of immunoglobulin light chain amyloidosis:mayo Stratification of Myeloma and Risk-Adapted Therapy (m SMART) consensus statement[J].Mayo Clin Proc, 2015, 90 (8) :1054-1081.
|